Northland Capital Markets Starts Zimmer Biomet (ZBH) at Market Perform

Northland Capital Markets analyst Jason Wittes initiates coverage on Zimmer Biomet (NYSE: ZBH) with a Market Perform rating and a price target of $150.00.

The analyst commented, "It's a long recovery story for CEO Bryan Hanson who joined in late 2017, and appears to have stabilized the business, with the stock reaching what we view as the long-term bull case target of $150. To get to the next level, Mr. Hanson is looking to boost growth to 4-5% from low single digits (normalized) through innovation and portfolio management. A reasonable goal, but even the company admits at least a couple of years off."

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.

Shares of Zimmer Biomet closed at $142.00 yesterday.

You May Also Be Interested In

• DA Davidson Starts Everus (ECG) at Buy
• Keefe, Bruyette & Woods Resumes Royal Bank of Canada (RY:CN) (RY) at Market Perform
• DA Davidson Starts Comfort Systems USA (FIX) at Buy